Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Hsu, Ching Sheng ^a,b   Chao, You Chen ^a,b   Lin, Hans Hsienhong ^a,b   Chen, Ding Shinn ^c,d,e   Kao, Jia Horng ^c,d  

^a Taipei Tzu Chi Hospital   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS;

EID: 84929224759     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09954     Document Type: Review

References (30)

1. Kao J. H. & Chen D. S. Transmission of hepatitis C virus in Asia: past and present perspectives. J. Gastroenterol Hepatol. 15 Suppl, E91-96 (2000).
2. Chen D. S. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 25, 27-32 (1995).
3. Hsu C. S. et al. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One. 8, e70458 (2013).
4. Di Bisceglie A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl. J. Med. 359, 2429-2441 (2008).
5. Bruix J. et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 140, 1990-1999 (2011).
6. Hsu C. S. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl. J. Med. 369, 678 (2013).
7. Shiratori Y. et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 138, 299-306 (2003).
8. Kubo S. et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 134, 963-967 (2001).
9. Ikeda K. et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 32, 228-232 (2000).
10. Mazzaferro V. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 44, 1543-1554 (2006).
11. Ishikawa T. et al. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology. 59, 529-532 (2012).
12. Miyaguchi S. et al. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology. 49, 724-729 (2002).
13. Moher D., Liberati A., Tetzlaff J. & Altman D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).
14. Higgins J. P. et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 343, d5928 (2011).
15. Lok A. S. et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 140, 840-849 (2011).
16. Bernardinello E. et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology. 46, 3216-3222 (1999).
17. Valla D. C. et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 29, 1870-1875 (1999).
18. Nishiguchi S. et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346, 1051-1055 (1995).
19. Nishiguchi S., Tamori A. & Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 48, 71-75 (2005).
20. Kubo S. et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br. J. Surg. 89, 418-422 (2002).
21. Ghany M. G., Strader D. B., Thomas D. L. & Seeff L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 49, 1335-1374 (2009).
22. Lawitz E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887 (2013).
23. Yano H. et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology. 29, 1708-1717 (1999).
24. Kusano H. et al. Pegylated interferon-alpha2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One. 8, e83195 (2013).
25. Easterbrook P. J., Berlin J. A., Gopalan R. & Matthews D. R. Publication bias in clinical research. Lancet. 337, 867-872 (1991).
26. Wright R. W., Brand R. A., Dunn W. & Spindler K. P. How to write a systematic review. Clin. Orthop. Relat. Res. 455, 23-29 (2007).
27. Vale C. L., Tierney J. F. & Stewart L. A. Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int. J. Epidemiol. 31, 107-111 (2002).
28. Lawitz E. & Gane E. J. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 369, 678-679 (2013).
29. Lawitz E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887 (2013).
30. Jacobson I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867-1877 (2013).